Summary of COVID-19 lanadelumab studies

1. Amgen et al., Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

515 patient lanadelumab late treatment RCT: 7% higher mortality (p=1), 10% greater improvement (p=0.79), 24% higher hospital discharge (p=0.57), and 9% worse recovery (p=1).
RCT 55 hospitalized patients showing no significant difference with lanadelumab treatment.
Apr 2022, Amgen, NCT04590586, https://s3.amazonaws.com/trs-cor-9011/5014875/a260bd53-20a7-42af-8426-45d8d9087cf8/8b07f953-29ef-4571-855b-2a7918c21449/Public_Registration_(Study_Level)_-_Plain_Language_Summary_of_Results_V01_Global.en_-_07-Apr-2022_English-v1.pdf, https://c19p.org/amgenlan